Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on July 26, 2006
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyl067
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/9/557    most recent
hyl067v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Okusaka, T.
Right arrow Articles by Sumii, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okusaka, T.
Right arrow Articles by Sumii, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 Foundation for Promotion of Cancer Research
Received March 16, 2006
Accepted May 23, 2006

Original Article

A Phase I/II Study of Combination Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Cancer

Takuji Okusaka 1 *, Hiroshi Ishii 2, Akihiro Funakoshi 3, Hideki Ueno 1, Junji Furuse 2, and Toshihiko Sumii 3

1 Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
2 Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
3 Gastroenterology Division, National Kyushu Cancer Center, Fukuoka, Japan

* To whom correspondence should be addressed.
Takuji Okusaka, E-mail: tokusaka{at}ncc.go.jp


  Abstract

Background: In an effort to improve efficacy of single-agent gemcitabine in pancreatic cancer, several studies have examined the effects of 5-FU combined with gemcitabine. However, no studies to date have been performed in Japanese patients. We thus conducted a phase I/II study of gemcitabine and infusional 5-FU in Japanese patients to determine a recommended dosage for this combination and clarify efficacy and toxicity.

Methods: Phase I evaluated the frequency of dose limiting toxicity of two 5-FU dosages (400 and 500 mg/m2/day) infused continuously over 5 days combined with gemcitabine 1000 mg/m2 x 3 every 4 weeks. Results from phase I determined the recommended dosage to be examined in phase II for effect on survival period, clinical benefit response (CBR), tumor response and safety.

Results: A total of 34 chemo-naive patients were entered into the study. All had a Karnofsky performance of ≥50 points and distant metastases. Dose limiting toxicities in phase I determined the recommended 5-FU dosage at 400 mg/m2/day. Grade 3-4 hematological toxicities (neutropenia, leukopenia and thrombocytopenia) were the most common severe toxicities. For the 28 patients administered the recommended dosage, 1-year survival rate was 14.3%, median survival time 7.1 months and progression free survival 3.2 months. Seven patients achieved a 25% overall response rate and three showed 27.3% improvement in CBR.

Conclusion: Although a meaningful survival benefit over single-agent gemcitabine was not demonstrated, 5-FU 400 mg/m2/day infused continuously over 5 days in combination with gemcitabine 1000 mg/m2 x 3 every 4 weeks appeared to be a moderately effective palliative treatment with low toxicity in Japanese patients with metastatic pancreatic cancer.

Keywords: pancreatic cancer; phase I/II study; chemotherapy; gemcitabine; 5-FU.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.